Wood Mark Form 4 January 24, 2012

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

OMB APPROVAL OMB

3235-0287 Number:

Expires:

January 31, 2005

0.5

Estimated average burden hours per

response...

if no longer subject to Section 16. Form 4 or Form 5

Check this box

SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section may continue. 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

(Last)

See Instruction

1. Name and Address of Reporting Person * Wood Mark

2. Issuer Name and Ticker or Trading Symbol

Issuer

5. Relationship of Reporting Person(s) to

BIOMARIN PHARMACEUTICAL

(Check all applicable)

VP, Human Resources

INC [BMRN]

3. Date of Earliest Transaction (Month/Day/Year) 01/23/2012

Director 10% Owner Other (specify _X__ Officer (give title below)

C/O BIOMARIN PHARMACEUTICAL INC., 105

(First)

DIGITAL DRIVE

(Street)

4. If Amendment, Date Original

6. Individual or Joint/Group Filing(Check

Applicable Line)

Filed(Month/Day/Year)

(Middle)

X Form filed by One Reporting Person Form filed by More than One Reporting

Person

NOVATO, CA 94949

(City)	(State)	(Zip) Tabl	le I - Non-I	Derivative	Secu	rities Acqu	ired, Disposed of	, or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transactic Code (Instr. 8)	4. Securion(A) or D (Instr. 3,	ispose 4 and (A) or	d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/23/2012(1)	01/23/2012	M	83	A	\$ 17.86	20,717	D	
Common Stock	01/23/2012(1)	01/23/2012	M	938	A	\$ 14.39	21,655	D	
Common Stock	01/23/2012(1)	01/23/2012	M	833	A	\$ 21.51	22,488	D	
Common Stock	01/23/2012(1)	01/23/2012	S	1,854	D	\$ 34.963 (2)	20,634	D	

Edgar Filing: Wood Mark - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	onof Derivative	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to bu) Common Stock	\$ 17.86	01/23/2012(1)	01/23/2012	М	83	06/17/2009(3)	12/16/2018	Common Stock	83
Stock Option (right to buy) Common Stock	\$ 14.39	01/23/2012(1)	01/23/2012	М	938	11/12/2009 <u>(4)</u>	05/11/2019	Common Stock	938
Stock Option (right to buy) Common Stock	\$ 21.51	01/23/2012(1)	01/23/2012	М	833	11/12/2010 <u>(5)</u>	05/11/2020	Common Stock	833

Reporting Owners

Reporting Owner Name / Address	Keiationsinps					
	Director	10% Owner	Officer	Other		
Wood Mark			VP, Human Resources			
C/O BIOMARIN PHARMACEUTICAL INC.						

Reporting Owners 2

Dolotionchine

105 DIGITAL DRIVE NOVATO, CA 94949

Signatures

/s/ Laura Randall Woodhead, Attorney-in-Fact

01/24/2012

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Transaction made pursuant to a Rule 10b5-1 Trading plan executed on August 20, 2011.
- The price in Column 4 is a weighted average price. The prices actually received ranged from \$34.59 to \$35.40. The reporting person will (2) provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- (3) Original option grant vests 6/48th on June 17, 2009 and 1/48th each on the 17th of each month thereafter.
- (4) Original option grant vests 6/48th on November 12, 2009 and 1/48th each on the 12th of each month thereafter.
- (5) Original option grant vests 6/48th on November 12, 2010 and 1/48th each on the 12th of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3